The invention relates to novel 9H-pyrrolo[2,3-b: 5,4-c] dipyridine azacarbolines of formula (I), where: Z2, Z3, and Z4 are CH, CRa, CRs, or N R3 is H, Hal CF3, CHF2 OH, alkoxy NH2, NH (alkyl), N(alkyl)2 C(O)O alkyl CONH(alkyl), CON(alkyl)2 C1-C10 alkyl aryl heteroaryl R6 is heteroaryl Ra is CONH2, CONH alkyl, CONH cycloalkyl CONH heterocycloalkyl CON(alkyl)2 CON(alkyl)(heterocycloalkyl) CONHN(alkyl)2 C(O)heterocycloalkyl Rs is H Hal, OH O-alkyl(C1-C10) NH2 N(alkyl(C1-C10) or cycloalkyl(C3-C7))2 NHC(O)R3a N(alkyl(C1-C10)C(O)R3a NHS(O2)R3a N(alkyl(C1-C10)S(O2)R3a CO2R3a SR3a S(O)R3a S(O2)R3a Ra and Rs optionally form a cycle R3a is selected from among Hal, CF3, C1-C10 alkyl C3-C7 cycloalkyl C2-C6 alkenyl C2-C6 alkynyl OH O-alkyl(C1-C10) (C3-C7) heterocycloalkyl (C3-C7) NH2 NH-(alkyl(C1-C10) or cycloalkyl(C3-C7)) N(alkyl(C1-C10) or cycloalkyl(C3-C7))2 NH-(alkyl(C1-C10) or heterocycloalkyl(C3-C7)) N(alkyl(C1-C10) or heterocycloalkyl(C3-C7))2, as well as to the isomers and salts of said substances of formula (I) and to the therapeutic use thereof for treating cancer.Nouvelles azacarbolines 9H-pyrrolo [2,3-b:5,4-c]dipyridine de formule (I) : avec Z2, Z3, Z4 représentent CH, CRa, CRs ou N R3 représente H, HaI CF3, CHF20H, alkoxyNH2, NH(alkyle), N(alkyle)2 C(O)Oalkyle C0NH(alkyle),C0N(alkyle)2 C1 -C10 alkyle aryle hétéroaryle R6 représente hétéroaryle Ra représente CONH2, CONHalkyle,CONHcycloalkyle CONHhétérocycloalkyle CON(alkyle)2 CON(alkyle)(hétérocycloalkyle) CONHN(alkyle)2 C(O)hétérocycloalkyle Rs représente HHal, OH 0-alkyle(C1 - C10) NH2 N(alkyle(C1 -C10) ou cycloalkyle(C3-C7))2 NHC(O)R3a N(alkyle(C1 - C10)C(O)R3a NHS(O2)R3a N(alkyle(C1 -C10)S(O2)R3a CO2R3a SR3a S(O)R3aS(O2)R3a Ra et Rs forment éventuellement un cycle ??R3a étant choisi parmi HaI, CF3, C1 -C10 alkyle C3-C7 cycloalkyle C2-C6 alkenyle C2-C6 alkynyle OH O-alkyle(C1 -C10) (C3-C7) hétérocycloalkyle (C3-C7) NH2 NH- (alkyle(C1 -C10) ou cycloalkyle(C3-C7)) N(alkyle(C1 -C10) ou cycloalkyle(C3-C7))2 NH-(alkyle
